Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Impact of new medications on the treatment of immune TTP

Marie Scully, Lara Howells, William A. Lester

Blood (2025) 145 (13): 1353–1357.

https://doi.org/10.1182/blood.2024026390

Published: 2025

Journal Articles

Acute HUS: fast-track genetics

Marie Scully

Blood (2024) 144 (21): 2165–2167.

https://doi.org/10.1182/blood.2024026506

Published: 2024

Journal Articles

Recombinant ADAMTS13 Prophylaxis in Pediatric Patients with Congenital Thrombotic Thrombocytopenic Purpura: Results from the Phase 3 Randomized, Crossover Study and the Phase 3b Continuation Study

Marie Scully, Claire Berger, Nathalie Biebuyck, Santiago Bonanad Boix, Claire Dossier, Wolf-Achim Hassenpflug, Karim Kentouche, Beverly Schaefer, Silvia Maria Trisolini, Runhui Wu, Juan Xiao, Feng Xue, Björn Mellgård, Munjal Patel, Parth Patwari, Linda T. Wang, Shan Xiao, Pinghai Zhang

Blood (2024) 144 (Supplement 1): 141.

https://doi.org/10.1182/blood-2024-199087

Published: 2024

Journal Articles

The Quest for Effective and Well-Tolerated Treatment for Congenital TTP: Half a Century of Experience in the United Kingdom

Praveen Gounder, Louisa Keogh, William Lester, Amanda Clark, Joost Vanveen, Tina Dutt, Michael Desborough, Joannes Hermans, Alice Taylor, Marie Scully

Blood (2024) 144 (Supplement 1): 4005.

https://doi.org/10.1182/blood-2024-211041

Published: 2024

Journal Articles

Caplacizumab Resistance in Immune Thrombotic Thrombocytopenic Purpura (TTP) Mediated By VWF A1 Domain Missense Mutation

Mari Thomas, Imogen Buckle, Adela Constantinescu-Bercu, Rens De Groot, Arshia Latif, Sabina McCann, Marie Scully

Blood (2024) 144 (Supplement 1): 4004.

https://doi.org/10.1182/blood-2024-210866

Published: 2024

Journal Articles

Caplacizumab in Immune-Mediated Acquired Thrombotic Thrombocytopenic Purpura: A Systematic Literature Review and Meta-Analyses of Clinical Trials and Observational Studies

Paul Coppo, Marie Scully, Agathe Nevière, Pauline Le Nouveau, Prerna Patel, Alaeddine Sidhom, Srushhti Trivedi, Rachel Chu, Da Eun Ahn, Gabriela Marcheva, Divyesh Thakker, Gaye Siliman, Alix Arnaud

Blood (2024) 144 (Supplement 1): 4001.

https://doi.org/10.1182/blood-2024-204743

Published: 2024

Journal Articles

Clinical Outcomes of Immune-Mediated Thrombotic Thrombocytopenic Purpura from a Multinational Patient Population

Paul Coppo, Flora Peyvandi, Marie Scully, Johanna A. Kremer Hovinga, Ragy Saad, Maria Jose Aragon, Enrico Ferri Grazzi, Ping Du, Loredana Cuccia, Hamid Ferdosi

Blood (2024) 144 (Supplement 1): 5542.

https://doi.org/10.1182/blood-2024-208741

Published: 2024

Journal Articles

Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome

Spero R. Cataland, Paul Coppo, Marie Scully, Bernhard Lämmle

Blood (2024) 144 (11): 1143–1152.

https://doi.org/10.1182/blood.2023022277

Published: 2024

Journal Articles

Peak ADAMTS13 activity to assess ADAMTS13 conformation and risk of relapse in immune-mediated thrombotic thrombocytopenic purpura

Nithya Prasannan, Bertina Dragunaite, Maryam Subhan, Mari Thomas, Rens de Groot, Deepak Singh, Karen Vanhoorelbeke, Marie Scully

Blood (2024) 143 (25): 2644–2653.

https://doi.org/10.1182/blood.2023023269

Published: 2024

Includes: Supplemental data

Journal Articles

VITT-like disorder HITs the headlines

Marie Scully

Blood (2023) 142 (26): 2229–2230.

https://doi.org/10.1182/blood.2023022900

Published: 2023

Journal Articles

Pregnancy-Related Outcomes in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of a Retrospective Chart Review Study

PAUL Coppo, Marie Scully, Johanna A. Kremer Hovinga, Maria Jose Aragon, Parth Patwari, Linda T. Wang, Bjorn Mellgard, Olulade Ayodele, Ragy Saad

Blood (2023) 142 (Supplement 1): 1261.

https://doi.org/10.1182/blood-2023-189181

Published: 2023

Journal Articles

Comparing the Impact of Rituximab Dosing on Longitudinal ADAMTS13 Parameters in TTP

Maryam Subhan, Nithya Prasannan, Bertina Dragunaite, Karen Vanhoorelbeke, Marie Scully, Mari Thomas

Blood (2023) 142 (Supplement 1): 694.

https://doi.org/10.1182/blood-2023-190542

Published: 2023

Journal Articles

Clinical Outcomes of Congenital Thrombotic Thrombocytopenic Purpura: A Multinational Chart Review Study

PAUL Coppo, Marie Scully, Johanna A. Kremer Hovinga, Maria Jose Aragon, Parth Patwari, Linda T. Wang, Bjorn Mellgard, Olulade Ayodele, Ragy Saad

Blood (2023) 142 (Supplement 1): 4006.

https://doi.org/10.1182/blood-2023-189416

Published: 2023

Journal Articles

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

Blood (2023) 142 (Supplement 1): 2636.

https://doi.org/10.1182/blood-2023-179316

Published: 2023

Journal Articles

Recombinant ADAMTS13 for the Treatment of Acute TTP Events in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Results from the Phase 3 Randomized, Controlled, Crossover Study and the Phase 3b Continuation Study

Marie Scully, Thomas L. Ortel, Ziqiang Yu, Maria Waliullah, Pinghai Zhang, Munjal Patel, Parth Patwari, Bjorn Mellgard, Linda T. Wang

Blood (2023) 142 (Supplement 1): 692.

https://doi.org/10.1182/blood-2023-188996

Published: 2023

Journal Articles

Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab era

Nithya Prasannan, Mari Thomas, Matthew Stubbs, John-Paul Westwood, Rens de Groot, Deepak Singh, Marie Scully

Blood (2023) 141 (18): 2206–2213.

https://doi.org/10.1182/blood.2022018847

Published: 2023

Includes: Supplemental data

Journal Articles

Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy

Andrew J. Doyle, Matthew J. Stubbs, Tina Dutt, Will Lester, Will Thomas, Joost van Veen, Joannes Hermans, Tanya Cranfield, Quentin A. Hill, Amanda Clark, Catherine Bagot, Steven Austin, John-Paul Westwood, Mari Thomas, Marie Scully

Blood (2023) 141 (3): 285–294.

https://doi.org/10.1182/blood.2022017023

Published: 2023

Journal Articles

Coagulation Factor VIII Enhances the Cleavage of Von Willebrand Factor By ADAMTS13 In Vivo

Wenjing Cao, Aria Bales, Antonia Bignotti, Noritaka Yada, Liang Zheng, Lindsey George, Denise E. Sabatino, Marie Scully, Rodney M. Camire, X. Long Zheng

Blood (2022) 140 (Supplement 1): 5572–5573.

https://doi.org/10.1182/blood-2022-167539

Published: 2022

Journal Articles

The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies

Johanna A. Kremer Hovinga Strebel, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knoebl, Flora Peyvandi, Spero Cataland, PAUL Coppo, Umer Khan, Laurel A. Menapace, Ana Paula Marques, Sriya Gunawardena, Marie Scully

Blood (2022) 140 (Supplement 1): 5651–5653.

https://doi.org/10.1182/blood-2022-156306

Published: 2022

Journal Articles

Clinical features of thrombosis and bleeding in COVID-19

Mari R. Thomas, Marie Scully

Blood (2022) 140 (3): 184–195.

https://doi.org/10.1182/blood.2021012247

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of new medications on the treatment of immune TTP

Acute HUS: fast-track genetics

Recombinant ADAMTS13 Prophylaxis in Pediatric Patients with Congenital Thrombotic Thrombocytopenic Purpura: Results from the Phase 3 Randomized, Crossover Study and the Phase 3b Continuation Study

The Quest for Effective and Well-Tolerated Treatment for Congenital TTP: Half a Century of Experience in the United Kingdom

Caplacizumab Resistance in Immune Thrombotic Thrombocytopenic Purpura (TTP) Mediated By VWF A1 Domain Missense Mutation

Caplacizumab in Immune-Mediated Acquired Thrombotic Thrombocytopenic Purpura: A Systematic Literature Review and Meta-Analyses of Clinical Trials and Observational Studies

Clinical Outcomes of Immune-Mediated Thrombotic Thrombocytopenic Purpura from a Multinational Patient Population

Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome

Peak ADAMTS13 activity to assess ADAMTS13 conformation and risk of relapse in immune-mediated thrombotic thrombocytopenic purpura

VITT-like disorder HITs the headlines

Pregnancy-Related Outcomes in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of a Retrospective Chart Review Study

Comparing the Impact of Rituximab Dosing on Longitudinal ADAMTS13 Parameters in TTP

Clinical Outcomes of Congenital Thrombotic Thrombocytopenic Purpura: A Multinational Chart Review Study

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

Recombinant ADAMTS13 for the Treatment of Acute TTP Events in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Results from the Phase 3 Randomized, Controlled, Crossover Study and the Phase 3b Continuation Study

Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab era

Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy

Coagulation Factor VIII Enhances the Cleavage of Von Willebrand Factor By ADAMTS13 In Vivo

The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies

Clinical features of thrombosis and bleeding in COVID-19

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only